Jun 4, 2021 · Wegovy™ is the first and only once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management for people living with obesity. The approval is based on the results from the STEP phase 3a clinical trial programme.

6 Investor presentation First nine months of 2024 Novo Nordisk has tripled its glob increased its GLP-1 volume mark Global number of patients on GLP-1s acr

Bagsværd, Denmark, 22 May 2023 – Novo Nordisk today announced headline results from OASIS 1, a phase 3a trial in the global OASIS programme. OASIS 1 is a 68-week, efficacy and safety trial comparing once-daily oral semaglutide 50 mg for weight management to placebo in 667 adults with obesity or overweight with one or more comorbidities.

Sep 20, 2019 · Rybelsus ®, the brand name for oral semaglutide in the US, is the first approved glucagon-like peptide-1 (GLP-1) receptor agonist in a tablet. The approval of Rybelsus ® is based on the results from 10 PIONEER clinical trials which included 9,543 adults with type 2 diabetes.

Novo Nordisk A/S Novo Alle 1 2880 Bagsværd Denmark +45-4444-8888 CVR-no. 24256790 Our medicines are for the approved indication for which they are authorised in the local country or region. For more information, please visit our product page

GLP-1 class expansion accelerates in the US in the first quarter of 2023 with volume growth across our portfolio NBRx: New-to-brand prescriptions; TRx: Total prescriptions; NN: Novo Nordisk; Scripts: Prescriptions; US: United States Note: Class growth calculated as Q1 2023 vs Q1 2022 Source: IQVIA Xponent, NBRx data from week ending 14 Apr 2023.

• Novo Nordisk continues to be the global market leader in the GLP-1 segment with a 54.8% value market share • Estimated global GLP-1 share of total diabetes

Sources: Patient data is Novo Nordisk estimates; Value data: 2018 and 2021 data based on company reported sales for insulin, GLP-1, SGLT-2i and DPP-4i and IQVIA data for traditional OADs as of December 2018 and 2021

Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.